EP0136694A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Production of monomeric human gamma-interferon
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1984-10-02
•
Granted: —
•
Expires: 2004-10-02
Abstract
Abstract Monomeric human -y-interferon is efficiently produced by subjecting crude human γ-interferon to gel filtration under the coexistence of a reducing sulfur compound and a protein-denaturing agent.
Inventors
- 👤 Kiyoshi Nara
- 👤 Susumu Honda
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-24 22:59
CPC Classifications
C; C12; C12N; C12N15/00; C07; C07K; C07K1/00; C07K1/107; C07K1/113; C07K1/1133; A; A61; A61P; A61P43/00; C07K14/00; C07K14/435; C07K14/52; C07K14/555; C07K14/57; C12N15/09; C12N15/63; C12N15/70; C12N15/71; Y; Y10; Y10S; Y10S435/00; Y10S435/811; Y10S930/00; Y10S930/01; Y10S930/14; Y10S930/142
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
28 words
A method for producing monomeric human y-interferon, which comprises subjecting crude human y-interferon to gel filtration under the coexistence of a reducing sulfur compound and a protein-denaturing agent.
Claim 2
Independent Claim
28 words
A method for producing monomeric human y-interferon, which comprises subjecting crude human y-interferon to gel filtration under the coexistence of a reducing sulfur compound and a protein-denaturing agent.
Claim 3
Dependent Claim
16 words
A method according to Claim 1, wherein the reducing sulfur compound is an organic sulfur compound.
Claim 4
Dependent Claim
39 words
A method according to Claim 2, wherein the organic sulfur compound is a member selected from a group consisting of cysteine, N-acetylcysteine, N-acetylhomocysteine, glutathione (reduced form), thioethanolamine, monothioglycerol, dithiothreitol, thioalkane having 1-7 carbon atoms and formaldehyde sodium sulfoxilate dihydrate.
Claim 5
Dependent Claim
15 words
A method according to Claim 3, wherein the organic sulfur compound is glutathione (reduced form).
Claim 6
Dependent Claim
24 words
A method according to Claim 1, wherein the protein-denaturing agent is a member selected from a group consisting of guanidine salt, urea and thiocyanate.
Claim 7
Dependent Claim
13 words
A method according to Claim 5, wherein the protein-denaturing agent is guanidine salt.
Claim 8
Dependent Claim
15 words
A method according to Claim 1, wherein the human y-interferon is a recombinant human y-interferon.
Claim 9
Dependent Claim
25 words
A method according to Claim 1, wherein the crude human y-interferon is an eluate of an antibody column loaded by an extract containing human y-interferon.
Claim 10
Dependent Claim
22 words
A method according to Claim 1, wherein the gel is a member selected from a group consisting of dextran, polyacrylamide and agarose.
Claim 11
Dependent Claim
12 words
A method according to Claim 9, wherein the gel is a dextran.
Claim 12
Dependent Claim
48 words
A method according to Claim 1, wherein the gel filtration is conducted by loading crude human y-interferon dissolved in a buffer solution containing a reducing sulfur compound and a protein-denaturing agent on a column packed with granular gel and then eluting the y-interferon by the same buffer solution.
Claim 13
Dependent Claim
33 words
A method according to Claim 11, wherein the buffer solution contains the reducing sulfur compound and the protein-denaturing agent in a concentration of 1 to 100 mM and 0.1 to 7 M, respectively.
Claim 14
Dependent Claim
16 words
A method according to Claim 11, wherein the buffer solution is of pH 5.0 to 8.0.
Claim 15
Dependent Claim
19 words
A method according to Claim 11, wherein the elution is conducted at a space velocity of 0.1 to 10.
Claim 16
Dependent Claim
42 words
A method according to Claim 1, wherein the resulting monomeric human y-interferon solution is further subjected to gel filtration using a gel suited for removing low molecular weight compounds to obtain monomeric human y-interferon free from reducing sulfur compound and protein-denaturing agent.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.